Literature DB >> 15541629

Psychotropic medication in adults with mental retardation: prevalence, and prescription practices.

Børge Holden1, Jens Petter Gitlesen.   

Abstract

People with mental retardation comprise an overmedicated population. Studies the last 20 years or so indicate that nearly 50% of people with mental retardation receiving care have been using psychotropic medication, in the treatment of psychiatric disorders and/or problem behaviours. The recent years guidelines for prescription of psychotropics have been developed, emphasizing, e.g. the presence of a diagnosis, consideration of alternatives, and evaluation. In spite of all this, we found that 37% of people with mental retardation in one Norwegian county were using psychotropics, mostly neuroleptics. Moreover, prescriptions frequently violated current guidelines, especially when conducted by general practitioners. For example, a lot of prescriptions had not been indicated by a diagnosis, alternatives to medications had rarely been explored, and evaluation of effects and side effects were exceptions. Psychiatrists complied more with current guidelines. Implications of the findings are discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15541629     DOI: 10.1016/j.ridd.2004.03.004

Source DB:  PubMed          Journal:  Res Dev Disabil        ISSN: 0891-4222


  19 in total

Review 1.  Medication use and potentially inappropriate prescribing in older adults with intellectual disabilities: a neglected area of research.

Authors:  Maire O'Dwyer; Philip McCallion; Mary McCarron; Martin Henman
Journal:  Ther Adv Drug Saf       Date:  2018-06-20

2.  Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative findings from a large scale study.

Authors:  John A Tsiouris; Soh-Yule Kim; W Ted Brown; Jill Pettinger; Ira L Cohen
Journal:  J Autism Dev Disord       Date:  2013-03

3.  [Determinants of psychotropic medication in adults with mild or moderate intellectual disabilities].

Authors:  M Schützwohl; E Voss; M Stiawa; H-J Salize; B Puschner; A Koch
Journal:  Nervenarzt       Date:  2017-11       Impact factor: 1.214

Review 4.  Issues in the management of challenging behaviours of adults with autism spectrum disorder.

Authors:  Johnny L Matson; Megan Sipes; Jill C Fodstad; Mary E Fitzgerald
Journal:  CNS Drugs       Date:  2011-07       Impact factor: 5.749

Review 5.  Tobacco use among individuals with intellectual or developmental disabilities: a brief review.

Authors:  Marc L Steinberg; Laura Heimlich; Jill M Williams
Journal:  Intellect Dev Disabil       Date:  2009-06

6.  Expanding Public Health Surveillance for People with Intellectual and Developmental Disabilities in the United States.

Authors:  Michael H Fox; Alexandra Bonardi; Gloria L Krahn
Journal:  Int Rev Res Dev Disabil       Date:  2015

7.  Pharmacogenomic Studies in Intellectual Disabilities and Autism Spectrum Disorder: A Systematic Review.

Authors:  Kazunari Yoshida; Emiko Koyama; Clement C Zai; Joseph H Beitchman; James L Kennedy; Yona Lunsky; Pushpal Desarkar; Daniel J Müller
Journal:  Can J Psychiatry       Date:  2020-11-23       Impact factor: 5.321

8.  Psychiatric disorders in adolescents and young adults with Down syndrome and other intellectual disabilities.

Authors:  Elisabeth M Dykens; Bhavik Shah; Bruce Davis; Courtney Baker; Taylor Fife; Jeri Fitzpatrick
Journal:  J Neurodev Disord       Date:  2015-03-01       Impact factor: 4.025

9.  Intellectual disability and mental health problems: a qualitative study of general practitioners' views.

Authors:  Terje Fredheim; Ole Rikard Haavet; Lars Johan Danbolt; Kari Kjønsberg; Lars Lien
Journal:  BMJ Open       Date:  2013-03-06       Impact factor: 2.692

10.  Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study.

Authors:  Rory Sheehan; Angela Hassiotis; Kate Walters; David Osborn; André Strydom; Laura Horsfall
Journal:  BMJ       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.